AP NEWS
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Globe Newswire
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

Uptick Newswire Hosts Premier Biomedical, Inc. on The Stock Day Podcast to Discuss the Company’s Current Projects

February 20, 2019

PHOENIX, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed Premier Biomedical, Inc. (BIEI), a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. President and CEO, William A. Hartman, joined Stock Day host Everett Jolly.

Jolly began the interview by asking Hartman to give an update to listeners about the Company’s current projects. Hartman explained the Company was previously strictly a R&D based business. This went well for the Company, they were forced to put their very successful projects, including a cure for PTSD as well as an anti-breast cancer drug on the shelf and morph the company into developing and marketing a revenue-producing series of hemp oil/CBD topical pain-relieving products.

To explain the Company’s current position, Hartman shared a letter with listeners that the company sent out recently to 29 of its Directors, Officers, and sales force. Hartman also stated that the letter would soon be sent out to the company’s stockholders and its e-mail distribution list.

The letter stated: “We currently have eight topical, all-natural, 50-state- legal, pesticide- and solvent-free, hemp oil/CBD, topical pain relief products that, we believe, are the very best on the market.”

Hartman shared that the products developed by the Company are created with a proprietary formula, which makes them more effective than competitors and at a lower price. “Unsolicited testimonies from satisfied customers validate our claims,” added Hartman.

Hartman also explained that the Company has sold most of their products online to date, with some smaller percentage of sales to pharmacies and medical facilities. However, the Company received a serious blow to its online sales when Amazon refused to list any products on their platform with CBD listed as an ingredient. Hartman is optimistic that the passing of the 2018 Farm Bill will eventually shift Amazon’s stance on the subject, but it may take some time.

In the interim, the Company will be reestablishing their position on Amazon by creating a product line labeled, “Nature’s Own Pain Relief”. This product line will not have CBD listed on the label and will therefore comply with Amazon’s guidelines. The Company will also be expanding their sales via direct distribution to retail establishments.

Premier Biomedical has recently been working with a large distributor that has access to convenience store marketing and sales. The distributor challenged the Company to produce a line of products that would retail for under ten dollars. Hartman explained that Premier worked very hard to develop a total of four new “Intro” products that would retail at or below this price point.

“We’re very excited about these new products, but unfortunately, manufacturing availability is waiting on the purchase order for some or all of these products from the distributor,” explained Hartman. He also added that he expects the purchase order to occur within the first quarter.

Hartman then shared that the distributor’s plan is to try these products out in up to 1,000 stores, and, if successful, expand into 10,000 stores nationwide. Meanwhile, the Company is working on preparing to market its entire line of Premium Products under the new name: “Nature’s Own Pain Relief” label.

The Company has also partnered with an additional distributor and will be altering their price points to perform more competitively in the market. Once these changes occur, the Company expects sales to increase exponentially.

Hartman explained that another distributorship for the Company revolves around military and long-term care sales, which represent massive potential revenues. Hartman emphasized that a major impetus in the growth of the hemp oil/CBD business is the fact that Premier’s products are an alternative to dangerous and addictive opioid pain medications that are a major contributor to the almost 200 drug overdose deaths per day in the country.

Hartman closed by sharing that the Company plans to proceed aggressively with their two-pronged sales strategy and expansion to become an even larger force in the industry. Hartman also shared his interest in potential partnerships, both domestic and foreign, and what they could mean for the potential of the Company.

To hear Premier Biomedical Inc.’s entire interview, follow the link to the podcast here: https://upticknewswire.com/featured-interview-ceo-william-hartman-of-premier-biomedical-inc-otcqb-biei-13/

Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/.

About Premier Biomedical, Inc.

Premier Biomedical, Inc. (OTC: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website: http://www.premierbiomedical.com/.

Contact:William A. HartmanPresident and CEOPremier Biomedical Inc.(724) 633-7033 w.hartman@premierbiomedical.comwww.premierbiomedical.com/

Safe Harbor NoticeCertain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

About Uptick Newswire and the “Stock Day” Podcast

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE:Uptick Newswire602-441-3474 https://upticknewswire.com/